Quotient Clinical
What do market changes mean for drug development?
Mark Egerton, CEO, Quotient Clinical, discusses reformulation drug development services for a changing market more
Acquisition expands Quotient’s formulation development services
Quotient Clinical has acquired formulation development specialist Co-Formulate Limited more
Quotient Clinical acquired by GHO Capital
Healthcare investor GHO Capital has acquired Quotient Clinical, a Translational Pharmaceutics company more
Sygnature Discovery delivers drug candidate
Sygnature Discovery has successfully delivered a drug candidate to Corcept Therapeutics. more
Honorary professorship for Quotient Clinical CSO
Quotient Clinical's chief scientific officer Dr Peter Scholes has been awarded an honorary professorship in the School of Pharmacy at the University of Nottingham. more
Quotient Clinical doubles pharma sciences capacity
Quotient Clinical has doubled capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories. more
Latest Formulation Optimisation Programme Accelerates Timelines by 50%
Quotient Clinical has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) programme — a significant milestone in the development of this service. more
Formulation Development and Clinical Testing Service to be Applied to Bronchodilator Therapy
Quotient Clinical has entered a collaboration with Pulmatrix Inc., a biotech company based in Massachusetts, US, to support the development of PUR0200, a new bronchodilator therapy for the treatment of chronic obstructive pulmonary disease and the... more
Formulation Development and Clinical Testing Service Extends into Non-Oral Routes of Delivery
Quotient Clinical, part of Quotient Bioresearch (Quotient), has announced that three new pharmaceutical and biotech clients have selected its RapidFACT service to support the development of optimal drug products for pulmonary, transdermal... more
